Battle Royale: Small molecules vs. biologics

The Inflation Reduction Act (IRA) allows the Centers for Medicare and Medicaid Services to negotiate drug prices. However, CMS can only negotiated drug prices 9 years after drug approval for small molecules and 13 years after approval for large molecules. Why the difference? Do biologic treatments produce superior health benefits for patients? This is the…

Read More

Would delinking PBM reimbursement from rebates save money?

According to a Health Affairs Scholar paper by Geoffrey Joyce out this month, the answer is ‘yes’. He writes: Most PBM contracts tie their compensation to a percentage of a drug’s list price, creating a financial incentive to favor high-cost, high-rebate drugs on plan formularies at the expense of lower-cost generics and biosimilars. Furthermore, the…

Read More

Broadening horizons in health technology

That is the title of an interview with me in The Evidence Base out today with the subtitle Introducing generalized cost effectiveness analysis for a comprehensive value assessment. Below is an excerpt: What is this paper about? What is new in this paper?Our recent publication presents a comprehensive framework for evaluating the societal value of health technologies,…

Read More

¿Un auto nuevo o un seguro médico? La cobertura familiar a través del empleo cuesta a los trabajadores hasta $27.000

El cierre del gobierno federal continúa, trabado por el desacuerdo en el Congreso sobre el costo del seguro médico de 22 millones de personas que tienen planes adquiridos en los mercados establecidos por la Ley de Cuidado de Salud a Bajo Precio (ACA). Mientras tanto, un nuevo informe muestra que más de 154 millones de personas con…

Read More